| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 32,816 | 31,169 | 26,595 | 18,146 | 19,561 |
| Sales Growth | +5.29% | +17.20% | +46.56% | -7.23% | -24.18% |
| Net Income | 2,058 | 2,670 | -4,461 | -9,663 | 23,477 |
| Net Income Growth | -22.91% | +159.85% | +53.84% | -141.16% | +437.69% |
Covalon Technologies Ltd (COV.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes and save lives in the areas of infection management, wound care, and surgical procedures. The company generates its revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products are CovaClear, IV IV Clear, SurgiClear, and VALGuard.
Fiscal Year End Date: 09/30